Comparison 4. Subgroup analysis: female versus male for the comparison of systemic corticosteroids versus standard care (plus/minus placebo) for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
4.1 All‐cause mortality up to 30 days	3	6788	Risk Ratio (M‐H, Random, 95% CI)	0.90 [0.83, 0.98]
4.1.1 Female	3	2475	Risk Ratio (M‐H, Random, 95% CI)	0.94 [0.81, 1.10]
4.1.2 Male	3	4313	Risk Ratio (M‐H, Random, 95% CI)	0.88 [0.80, 0.97]